Tech Company M&A Transactions
aFraxis Acquisition
aFraxis, operating out of La Jolla, was bought by Genentech. The transaction price was $187.5 million.
Transaction Overview
Company Name
Acquired By
Announced On
1/31/2013
Transaction Type
M&A
Amount
$187,500,000
M&A Terms
Under the terms of the agreement, Genentech willhave exclusive, worldwide rights to develop and commercialize Afraxis'proprietary compounds. Afraxis is eligible to receive upfront, research,development and commercialization milestone payments, together totaling up to $187.5 million.
Company Information
Company Status
Acquired or Merged
Industry
Biopharmaceutical
Mailing Address
11099 N Torrey Pines Rd. 290
La Jolla, CA 92037
USA
La Jolla, CA 92037
USA
Phone
Website
Email Address
Overview
Afraxis is discovering and developing drugs to treat diseases of the central nervous system, including schizophrenia, Alzheimer's disease, Fragile X syndrome and autism spectrum disorders. Recent scientific discoveries have linked these disorders to underlying defects in the development and function of specialized structures of the neural synapse, called dendritic spines.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Jay Lichter
Chief Scientific Officer
David Campbell
VP - Bus. Development
Carmine Stengone
VP - R & D
Christopher Rex
Browse more venture capital transactions:
Prev: 1/31/2013: nFluence Media venture capital transaction
Next: 1/31/2013: 42Floors venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. VC investment data records on this site come from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs